Recent Analysts’ Ratings Updates for CareDx (CDNA)

by · The Markets Daily

A number of firms have modified their ratings and price targets on shares of CareDx (NASDAQ: CDNA) recently:

  • 11/5/2026 – CareDx was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 10/31/2026 – CareDx was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 10/30/2026 – CareDx had its price target raised by BTIG Research from $81.00 to $92.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – CareDx was given a new $99.00 price target by Canaccord Genuity Group.
  • 10/27/2026 – CareDx had its price target raised by BTIG Research from $74.00 to $81.00. They now have a “buy” rating on the stock.
  • 10/19/2026 – CareDx had its price target raised by Canaccord Genuity Group from $65.00 to $80.00. They now have a “buy” rating on the stock.
  • 10/8/2026 – CareDx was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
  • 10/2/2026 – CareDx was downgraded by Zacks Research from “strong-buy” to “hold”.
  • 9/24/2026 – CareDx had its price target raised by BTIG Research from $60.00 to $74.00. They now have a “buy” rating on the stock.

CareDx Trading Down 4.3%

CDNA opened at $80.77 on Wednesday. CareDx, Inc. has a 12-month low of $15.15 and a 12-month high of $90.87. The business’s fifty day simple moving average is $64.53 and its 200-day simple moving average is $35.82. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of 33.80 and a beta of 2.50.

CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.45. The firm had revenue of $139.36 million during the quarter, compared to the consensus estimate of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The firm’s quarterly revenue was up 39.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 earnings per share. On average, equities research analysts predict that CareDx, Inc. will post 0.99 EPS for the current year.

Insider Activity

In related news, CFO Keith Kennedy sold 61,961 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $77.82, for a total value of $4,821,805.02. Following the transaction, the chief financial officer directly owned 199,147 shares of the company’s stock, valued at $15,497,619.54. This represents a 23.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.40% of the company’s stock.

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Read More